Literature DB >> 11790767

Identification of the critical features of a small peptide inhibitor of JNK activity.

Renae K Barr1, Tulene S Kendrick, Marie A Bogoyevitch.   

Abstract

The c-Jun N-terminal kinases (JNKs) are a subfamily of the mitogen-activated protein kinases (MAPKs). Although progress in evaluating the functions of other MAPKs has been facilitated by the characterization of specific inhibitors, no JNK-directed inhibitor is commercially available. We have identified a 21-amino acid peptide inhibitor of activated JNKs, based on amino acids 143-163 of the JNK-binding domain (JBD) of the JNK scaffolding protein, JNK-interacting protein-1 (JIP-1). This peptide, I-JIP (Inhibitor of JNK-based on JIP-1), inhibited JNK activity in vitro toward recombinant c-Jun, Elk, and ATF2 up to 90%. A truncated I-JIP (TI-JIP), the C-terminal 11 amino acids of I-JIP, directly interacted with recombinant JNKs but not its substrates as shown by surface plasmon resonance analysis. Scanning alanine replacement within truncated I-JIP identified 4 residues (Arg-156, Pro-157, Leu-160, or Leu-162) as independently critical for inhibition. JBD peptide sequences from JIP-2 and JIP-3 shared these critical residues and accordingly were effective JNK inhibitors. In contrast, peptides based on the JBDs of ATF2 and c-Jun inhibited JNK activity by <40%, which agreed with their lack of homology to the critical Arg-156 and Pro-157. These studies thus define a small peptide inhibitor sequence of JNKs based on the JIP proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790767     DOI: 10.1074/jbc.M107565200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease.

Authors:  Steven P Braithwaite; Ralf S Schmid; Dong Ning He; Mei-Li A Sung; Seongeon Cho; Lynn Resnick; Michael M Monaghan; Warren D Hirst; Christian Essrich; Peter H Reinhart; Donald C Lo
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

2.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 3.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

4.  Nerve growth factor-induced cell cycle reentry in newborn neurons is triggered by p38MAPK-dependent E2F4 phosphorylation.

Authors:  Sandra M Morillo; Erika P Abanto; María J Román; José M Frade
Journal:  Mol Cell Biol       Date:  2012-05-14       Impact factor: 4.272

5.  Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors.

Authors:  Chloe K Lombard; Audrey L Davis; Takayuki Inukai; Dustin J Maly
Journal:  Biochemistry       Date:  2018-09-25       Impact factor: 3.162

6.  Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.

Authors:  John L Stebbins; Surya K De; Petra Pavlickova; Vida Chen; Thomas Machleidt; Li-Hsing Chen; Christian Kuntzen; Shinichi Kitada; Michael Karin; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2011-08-23       Impact factor: 7.446

7.  Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.

Authors:  Sumit Bhattacharyya; Leo Feferman; Xiaorui Han; Yilan Ouyang; Fuming Zhang; Robert J Linhardt; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

8.  Development of paramagnetic probes for molecular recognition studies in protein kinases.

Authors:  Jesus Vazquez; Surya K De; Li-Hsing Chen; Megan Riel-Mehan; Aras Emdadi; Jason Cellitti; John L Stebbins; Michele F Rega; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

9.  Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinase.

Authors:  J David Beckham; Robin J Goody; Penny Clarke; Christophe Bonny; Kenneth L Tyler
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation.

Authors:  Jesse E Otero; Simon Dai; Domenica Foglia; Muhammad Alhawagri; Jean Vacher; Manolis Pasparakis; Yousef Abu-Amer
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.